DEPARTMENT OF PSYCHIATRY. Newsletter

Similar documents
DEPARTMENT OF PSYCHIATRY. Newsletter

DEPARTMENT OF PSYCHIATRY. Newsletter

DEPARTMENT OF PSYCHIATRY. Newsletter

DEPARTMENT OF PSYCHIATRY. Newsletter

DEPARTMENT OF PSYCHIATRY. Newsletter

University of South Florida OCD, Anxiety, and Related Disorders Behavioral Treatment Program

An Update on the Treatment of Obsessive Compulsive Disorder In Children and Adolescents

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX

Intensive Treatment Program Interview with Dr. Eric Storch of The University of South Florida OCD Program in St. Petersburg, Florida January 2009

Jennifer Zarcone. Kennedy Krieger Institute and Johns Hopkins School of Medicine

Taking Care: Child and Youth Mental Health TREATMENT OPTIONS

Treatment Options for Bipolar Disorder Contents

Average dose zoloft for ocd and anxiety

Depression & Anxiety in Adolescents

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

Curriculum Vitae, Carmen Zegarra, M.D. Carmen Zegarra, M.D. FutureSearch Clinical Trials, L.P Parkcrest Drive, Suite 300 Austin, TX 78731

Clinical Policy: Clomipramine (Anafranil) Reference Number: HIM.PA.149 Effective Date: Last Review Date: 05.18

NEWS. In this Issue: November Clinical Conversation: Understanding PANS and PANDAS. Leadership: John Straus, MD Founding Director

HDSA welcomes you to Caregiver s Corner. Funded by an educational grant from

Management Of Depression And Anxiety

Change Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness

Obsessive-Compulsive Disorder

Medications in Autism: What We Know and Don't Know

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

PANS-PANDAS An Update on Research and Clinical Management

PANDAS/PANS DIAGNOSIS AND TREATMENT. Sophie Fowler FNP-BC

Jennifer M. Lytle, M.D., M.P.H. Clinical Trials of the Rockies 3955 E. Exposition Avenue, Suite 100 Denver, CO Tel.

2. You must remain available until at least 5:00PM each day unless approved by the Attending and Resident.

Steps for Initiating Electroconvulsive Therapy Treatment

Pharmacotherapy of OCD

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) Brittany Andry, MD PGY III Pediatric Resident LSUHSC

Our faculty has been hand-picked for their knowledge, experience, and enthusiasm for teaching

11/12/2017. How effective are treatments of psychiatric disorders in children and adolescents?

MODEL PSYCHOPHARMACOLOGY CURRICULUM

Obsessive/Compulsive Disorder

Psychiatry Resident Profile

Advocating for people with mental health needs and developmental disability GLOSSARY

SECTION 1. Children and Adolescents with Depressive Disorder: Summary of Findings. from the Literature and Clinical Consultation in Ontario

The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD

Treatment of Children with Mental Disorders

HDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D.

Mental/Emotional Health Problems. Mood Disorders and Anxiety Disorders

Website. All the benefits of sponsorship are detailed in the enclosed information.

Sally Anglim Friends of the Falcons Gala Event Coordinator

Mar 6, The most effective medications are described in the next section. Selective serotonin reuptake inhibitors (SSRIs) SSRIs are a highly

First Year Clinical Services

The Cheers Gala PARTNERSHIP OPPORTUNITIES

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

SPONSORSHIP OPPORTUNITIES & BENEFIT PACKAGES

PANDAS. Learning Objectives. What is PANDAS? Definition. 1- List the symptoms associated with PANDAS. 2- Describe the biological mechanism for PANDAS

Drugs, Society and Behavior

Young Friends of St. Louis Children s Hospital COCKTAILS & CLOWNS. Benefitting the Clown Docs at St. Louis Children s Hospital

Psychiatric Medications. Positive and negative effects in the classroom

6/22/2012. Co-morbidity - when two or more conditions occur together. The two conditions may or may not be causally related.

Thompson Centre Intensive Treatment Program Physician Referral Form

Child and Adolescent Psychopharmacology Made Simple (2nd edition)

Pharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines

Establishing the Link: Assessment and Intervention of Children and Adults October 23, 2018

Things You Might Not Know About Psychotropic Medications But Wish You Did

Let s Talk About Treatment

Illuminating the Black Box: Antidepressants, Youth and Suicide

Disclosures. Learning Objectives. Psychopharmacology of Pediatric Anxiety and Depression 5/4/2017

5 COMMON QUESTIONS WHEN TREATING DEPRESSION

Curriculum Vitae, Glenn Michael Dempsey, M.D.

Guide to Psychiatric Medications for Children and Adolescents

Dear Friends, Dreams, hope, love, future, change, faith, imagination, trust, possibilities

Compassionate care and the hope you ve been seeking.

Curriculum Vitae, Glenn Michael Dempsey, M.D.

Curriculum Vitae, Conrad O. Beckles, M.S., L.M.H.C., Ph.D.

Asperger s Syndrome. severe difficulties interacting socially (Gillberg 2002). He named this difficulty

Pediatric Psychopharmacology

Curriculum Vitae (updated 10/31/16)

Depression and Anxiety. What is Depression? What is Depression? By Christopher Okiishi, MD Spring Not just being sad A syndrome of symptoms

Hispanic Business Student Association

ANNUAL COMMUNITY BREAKFAST SPONSORSHIP OPPORTUNITIES

PSYCHIATRY ALERTS CHILD& ADOLESCENT. Severe Mood Dysregulation or Bipolar Disorder?

Anti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of.

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

An Overview of Anxiety and Mood Disorders in Youth

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder

DECEMBER Meetings and Events Schedule. Second Tuesday of the Month NAMI Connection 5:30 pm - DEC. 8 TH START TIME. Third Monday of the Month

for anxious and avoidant behaviors.

Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol

Richard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA

Rochester High School s 5 th Annual Friends of the Falcons Gala

Obsessive-Compulsive Disorder

Diabetes and Depression. Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C

2017 Donald H. Gemson Cancer Research & Public Policy Breakfast

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:

Wednesday, June 3, 2015

Pharmacotherapy of OCD

Transcription:

DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of May 21-25, 2012 Website: http://www.hsc.usf.edu/psych/ Newsletter The University of South Florida Department of Psychiatry would like to cordially invite you to the 2012 Graduation, on Friday, June 15, 2012. As in past years, it is a momentous occasion for the graduating residents and fellows, their families, and faculty. This year, the celebration will include dinner, open bar and the traditional recognition of residents and faculty at The Columbia Restaurant, 2117 E. 7th Ave., in historic Ybor City from 6 pm- 10 pm. Please join us as we celebrate the completion of psychiatric training, years of great friendships, and the beginning of new journeys. Donations are also welcome to assist with sponsoring this event, of which a portion is tax deductible. All donations of $200 or greater include two tickets to the event. Your support is greatly appreciated and one of the following options may be appropriate for you. Platinum: $500, Gold: $400, Silver: $300, or Bronze Recognition: $200. Individual and guest tickets are available for $60. The amount of your payment, less the fair market value of goods and service received may be tax deductible. Please R.S.V.P. by May 31, 2012 to kisaac@health.usf.edu. Mail checks to 3515 E. Fletcher Ave. Tampa, FL, 33613, Attn: Kay Isaac. Please make your check payable to USF Foundation with 25-0147 on the memo line. Thank you again for your support of our graduation and educational program, and hope to see you at our celebration! Meetings Tuesday 05/22/12 12:00 noon No Grand Rounds Thursday 05/24/12 8:00 a.m. Call Center Meeting Resident Lectures: 8:00 a.m. PGY-3 Psychodynamic Theories Self Psychology Dr. Edward Stein CHILD Psychopharm Case Conference Dr. Amit Razdan 9:00 a.m. PGY-3 Clinical Case Conference Dr. Kailie Shaw and Beth Reese, LCSW CHILD Consultation Liaison Dr. Karen Goldberg 10:00 a.m. PGY-3 & PGY-4 Board Review Series Sleep Dr. Gootam CHILD Billing: Using Medical Codes Sara Cubilete

11:00 a.m. Residents Meeting 1:00 p.m. PGY-1 Bipolar Diagnosis Dr. Derrek Robben PGY-2 Psychiatric Care at the End of Life Dr. Jonathan Stewart GERI Ethic and Legal Aspect in Geriatric Psychiatry Dr. Ryan Estevez 2:00 p.m. PGY-1 Bipolar Treatment Dr. Derrek Robben PGY-2 Sleep Related Problems in the Elderly Dr. Connie Poetter 4:00 p.m. PGY-1 Substance Abuse Dr. Elie Frances Friday 05/25/12 Third Year Medical Student Lectures: 8:30 a.m. Psychiatry NBME 1:00 p.m. Neurology Exam In The Know! Happy Birthday wishes to Michelle Boundy/May 21 st, Dr. Daniel Fallon/May 22 nd, Melanie Engberg/May 25 th and Dr. Kimberly Hartney/May 27 th. To access a recent ABC Action News report regarding Dr. Michael Schoenberg s view on new multi-tasking studies that suggest neither success nor failure, click on the following link: http://www2.abcactionnews.com/dpp/news/health/local-expert-weightsin-on-new-multi-tasking-studies-that-suggest-neither-success-nor-failure For information regarding the USF Memory Disorders Clinic, please click on the following link: http://health.usf.edu/medicine/psychiatry/p_memory_disorders_clinic.htm Research Happenings! For information regarding current clinical trials, please go to the following website: http://health.usf.edu/medicine/psychiatry/index.htm Current Open Studies Call 813-974-2832 or 813-974-1404 for more information on any study or to refer a patient. Bipolar I in Teens This study is a 3- week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder experiencing a manic or mixed episode. A 26-week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator Mike Bengtson, MD.

Now Enrolling Bipolar A 9-month outpatient study of Ramelteon sub-lingual as an adjunctive treatment to prevent relapse of manic/mixed/depressive symptoms in patients 18-75 years who have experienced a manic/mixed/depressed episode within the last 9 months. Patients will continue on current mood stabilizers, antidepressants, or antipsychotic medications throughout the trial. PI Carlos Santana, MD Now Enrolling Bipolar I Disorder with Depressive Symptoms An 8-week outpatient study assessing Ramelteon sub-lingual as an adjunctive treatment for patients 18-75 years who are currently experiencing depressive symptoms associated with Bipolar I Disorder. Patients must be on Lithium and/or Depakote. PI Carlos Santana, MD Now Enrolling Schizophrenia Long-Acting IM Depot Open-label Study An open-label naturalistic study of Aripirazole IM (long-acting depot) in patients with schizophrenia 18-65 years. Patients must have been prescribed antipsychotic medication for at least 7 months prior to enrollment and have had at least 1 Inpatient Hospitalization in the past 24 months. PI Carlos Santana, MD http://health.usf.edu/medicine/psychiatry/research/index.htm Antibiotic Treatment Trial for the PANDAS/PANS Phenotype The purpose of this research study is to know if the antibiotic azithromycin improves symptom severity in children with sudden and severe onset obsessive compulsive symptoms known as PANS, Pediatric Acute Onset Neuropsychiatric Syndrome, and PANDAS, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus. This study seeks to compare the effects of placebo vs. azithromycin on symptom severity as well as to assess immune risk factors in children with PANDAS/PANS. Your child is being asked to take part in this research study because he/she may meet criteria for PANS/PANDAS and has a current episode of Obsessive- Compulsive Disorder (OCD) symptoms of less than or equal to 6 months that has been associated with an infection. Children ages 4-14 years old who are not currently taking prophylactic antibiotics or undergoing cognitive behavioral therapy (CBT) are eligible to participate. Please call (727) 767-8230 for more information. Quality of Life in Youth with Tic Disorders A one-time study visit evaluating the quality of life in youth with tic disorders, specifically on various aspects of family functioning and the daily challenges faced by children and their families. Children ages 6-17 years old with a diagnosis of a tic disorder (i.e. Chronic tic disorder or Tourette Syndrome) and are experiencing current tics are eligible to participate. This study is a one-time visit that will include questionnaires and assessments. Participants will also have the opportunity to attend a focus group with youth of similar age assessing kinds of help they received and accessibility of services and the difficulties faced by having tics. Please call (727) 767-8230 for more information.

Child and Adolescent Tourette s Disorder Guanfacine Clinical Trial The purpose of this research study is to learn more about the new extended release formula of the drug, guanfacine. This new formula is called Intuniv. This study will help us understand how safe and how well this new extended release formula of guanfacine works for children with chronic tics. Your child is being asked to take part in this research study because he/she has been diagnosed with Chronic Motor or Vocal Tic Disorder or Tourette s Disorder. Main symptoms are motor tics such as uncontrolled movements and/or vocal tics such as repeated noises. These tics occur many times a day, nearly every day lasting for at least 1 year. Children ages 6-17 years old are eligible to participate.please call (727) 767-8230 for more information. Living with Tics:The Living with Tics research study hopes to show how well a type of psychotherapy helps children better cope with tics and become more resilient. Children who are interested to participate must attend an initial assessment to determine eligibility. Eligible participants must be between 8 and 18 years of age, have a diagnosis of Tourette Syndrome or Chronic Tic Disorder, experience tic-related impairment, and either be medication-free or on stable medication. If eligible, interested participants will be randomly assigned to receive immediate psychotherapy or a 10 week waitlist control condition followed by subsequent psychotherapy. As part of the study, there is no charge for the psychotherapy treatment. The immediate psychotherapy condition consists of weekly therapy sessions over a 10 week period. This multi-component treatment approach includes habit reversal training, anger management, problem solving skills and other related therapeutic components to help improve the quality of life for children with chronic tic disorders. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD. Adult OCD Ondansetron Clinical Trial The purpose of this research study is to investigate the effectiveness, safety, and tolerability of 2 dosages Ondansetron as compared to placebo (a substance which looks like an active drug but has no active ingredient) in adult who have OCD and who are currently taking a selective serotonin reuptake inhibitor (SRI) such as Anafranil (clomipramine) Paxil (paroxetine), Prozac (fluoxetine), Luvox (fluvoxamine, or Zoloft (sertraline). Another purpose of this study is to find out how the study drug works in the body when taken along with an SSRI. Please call (727) 767-8230 for more information. Pediatric OCD D-Cycloserine and Cognitive Behavioral Therapy (CBT) Research Study The purpose of this research study is to examine if d-cycloserine enhances cognitive behavioral therapy for pediatric OCD. Participants will be involved in fifteen clinical visits spanning a nine-month period. Each participant will receive ten sessions of cognitive behavioral therapy and seven doses of the study medication or placebo one hour prior to session. Children ages 7-17 years old are eligible to participate. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD

Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study The purpose of this research study is to examine the efficacy of a manualized cognitive-behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 7-16 years old are eligible to participate. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD